» Articles » PMID: 12061431

Antitumor Effect of Bothrops Jararaca Venom

Overview
Publisher Wiley
Specialties Biochemistry
Pathology
Date 2002 Jun 14
PMID 12061431
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Many experimental studies have been carried out using snake venoms for the treatment of animal tumors, with controversial results. While some authors have reported an antitumor effect of treatment with specific snake venom fractions, others have reported no effects after this treatment. The aim of this study was to evaluate the effect of Bothrops jararaca venom (BjV) on Ehrlich ascites tumor (EAT) cells in vivo and in vitro. In the in vivo study, Swiss mice were inoculated with EAT cells by the intraperitoneal (i.p.) route and treated with BjV venom (0.4 mg/kg, i.p.), on the 1st, 4th, 7th, 10th, and 13th days. Mice were evaluated for total and differential cells number on the 2nd, 5th, 8th, 11th and 14th days. The survival time was also evaluated after 60 days of tumor growth. In the in vitro study, EAT and normal peritoneal cells were cultivated in the presence of different BjV concentrations (2.5, 5.0, 10.0, 20.0, 40.0, and 80 microg) and viability was verified after 3, 6, 12 and 24 h of cultivation. Results were analyzed statistically by the Kruskal-Wallis and Tukey tests at the 5% level of significance. It was observed that in vivo treatment with BjV induced tumor growth inhibition, increased animal survival time, decreased mortality, increased the influx of polymorphonuclear leukocytes on the early stages of tumor growth, and did not affect the mononuclear cells number. In vitro treatment with BjV produced a dose-dependent toxic effect on EAT and peritoneal cells, with higher effects against peritoneal cells. Taken together, our results demonstrate that BjV has an important antitumor effect. This is the first report showing this in vivo effect for this venom.

Citing Articles

Bothrops Jararaca Snake Venom Modulates Key Cancer-Related Proteins in Breast Tumor Cell Lines.

Kisaki C, Arcos S, Montoni F, da Silva Santos W, Calacina H, Lima I Toxins (Basel). 2021; 13(8).

PMID: 34437390 PMC: 8402457. DOI: 10.3390/toxins13080519.


Hitchhiking with Nature: Snake Venom Peptides to Fight Cancer and Superbugs.

Perez-Peinado C, Defaus S, Andreu D Toxins (Basel). 2020; 12(4).

PMID: 32326531 PMC: 7232197. DOI: 10.3390/toxins12040255.


Animal Toxins as Therapeutic Tools to Treat Neurodegenerative Diseases.

de Souza J, Goncalves B, Gomez M, Vieira L, Ribeiro F Front Pharmacol. 2018; 9:145.

PMID: 29527170 PMC: 5829052. DOI: 10.3389/fphar.2018.00145.


Modulation of Cytokines Production by Indomethacin Acute Dose during the Evolution of Ehrlich Ascites Tumor in Mice.

Gentile L, Queiroz-Hazarbassanov N, de Oliveira Massoco C, Fecchio D Mediators Inflamm. 2015; 2015:924028.

PMID: 26347589 PMC: 4549603. DOI: 10.1155/2015/924028.


Necrotic Effect versus Apoptotic Nature of Camptothecin in Human Cervical Cancer Cells.

Zare-Mirakabadi A, Sarzaeem A, Moradhaseli S, Sayad A, Negahdary M Iran J Cancer Prev. 2015; 5(3):109-16.

PMID: 25628829 PMC: 4294532.


References
1.
Gallagher G, Stimson W, Findlay J, Al-Azzawi F . Interleukin-6 enhances the induction of human lymphokine-activated killer cells. Cancer Immunol Immunother. 1990; 31(1):49-52. PMC: 11038205. DOI: 10.1007/BF01742495. View

2.
Luger T, Krutmann J, Kirnbauer R, Urbanski A, Schwarz T, Klappacher G . IFN-beta 2/IL-6 augments the activity of human natural killer cells. J Immunol. 1989; 143(4):1206-9. View

3.
Kitahara M, Kishimoto S, Hirano T, Kishimoto T, Okada M . The in vivo anti-tumor effect of human recombinant interleukin-6. Jpn J Cancer Res. 1990; 81(10):1032-8. PMC: 5917969. DOI: 10.1111/j.1349-7006.1990.tb03342.x. View

4.
Iho S, Shau H, Golub S . Characteristics of interleukin-6-enhanced lymphokine-activated killer cell function. Cell Immunol. 1991; 135(1):66-77. DOI: 10.1016/0008-8749(91)90254-9. View

5.
Borkow G, Ovadia M . Isolation and characterization of a cytotoxin P4 from the venom of Naja nigricollis nigricollis preferentially active on tumor cells. Biochem Int. 1991; 24(3):415-21. View